DSCSA Serialization Delay: Congress Extends 2025 Deadline

Congress Moves to Delay DSCSA Serialization to Prevent Drug Shortages

On January 15, 2025, the House Energy and Commerce Committee advanced H.R. 1233, the Drug Supply Chain Continuity Act, which would postpone full DSCSA serialization requirements from the statutory November 27, 2025 deadline to November 27, 2027. The bill passed committee by a 42-8 vote and now moves to the full House floor for consideration.

Regulatory Background

The Drug Supply Chain Security Act (DSCSA), enacted in 2013 as Title II of the Drug Quality and Security Act, established an electronic, interoperable system for identifying and tracing prescription drugs as they move through the U.S. supply chain. Under 21 U.S.C. § 360eee-1, the law requires all trading partners — manufacturers, wholesale drug distributors, repackagers, and dispensers — to exchange serialized product tracing information by November 27, 2025.

This means every saleable unit of prescription drugs must carry a unique product identifier, and each transaction must include serialized data transmitted via EPCIS-based systems. FDA enforcement of DSCSA serialization requirements began in phases: manufacturers and repackagers faced compliance deadlines starting in 2017, while wholesale distributors have been required to pass transaction information, transaction history, and transaction statements since January 1, 2015, but not yet at the serialized unit level.

The November 2025 deadline represents the final transition to full unit-level serialization across all trading partners. FDA issued its final guidance on enhanced drug distribution security in October 2023, clarifying verification and investigation requirements under the serialized system.

Congressional Action Details

H.R. 1233 provides a 24-month extension to the DSCSA compliance date for unit-level tracing. The bill does not alter the statutory framework itself — only the enforcement timeline. Key provisions include:

• Extension of the November 27, 2025 deadline to November 27, 2027 for all trading partners
• Preservation of existing product tracing requirements under 21 U.S.C. § 360eee-1(b), meaning lot-level transaction documentation remains in effect during the delay
• No modification to FDA's authority to enforce existing saleable returns requirements under 21 U.S.C. § 360eee-1(d)(4)
• Direction to FDA to issue interim guidance within 90 days of enactment regarding expectations for system readiness testing during the extension period

The bill's sponsors cited testimony from the Healthcare Distribution Alliance and the Generic Pharmaceutical Association, both of which warned that forced serialization by November 2025 would remove non-compliant trading partners from the supply chain and create immediate drug shortages for critical medications. The Congressional Budget Office estimated that 18-22% of wholesale drug distributors currently tracked in public databases have not completed EPCIS integration testing.

Impact on Wholesale Drug Distributors

The two-year delay directly affects operational timelines for wholesale drug distributors and 3PLs currently implementing DSCSA serialization infrastructure. Distributors that have not yet deployed EPCIS-capable warehouse management systems now have additional time to complete technology upgrades without risking enforcement action.

However, the delay does not eliminate compliance obligations — it postpones enforcement. Trading partners must continue to exchange transaction information, transaction history, and transaction statements at the lot level. Wholesale drug distributors remain subject to FDA inspection under 21 U.S.C. § 353(e), and failure to maintain product tracing records at the current lot level still constitutes a prohibited act under 21 U.S.C. § 331(t).

For distributors with active serialization projects, the delay introduces planning uncertainty. Capital expenditures scheduled for Q2-Q3 2025 may now be deferred to 2026-2027, but manufacturers and large distributors that have already deployed serialized systems are unlikely to roll back infrastructure. This creates a bifurcated supply chain: some trading partners exchanging serialized data voluntarily, others remaining at lot-level compliance.

The bill also affects verification requirements under 21 CFR 582.31. Distributors are currently required to verify product identifier on 10% of incoming saleable returns by November 27, 2025. The delay extends this timeline proportionally, though FDA's interim guidance (required within 90 days of enactment) will clarify whether voluntary verification pilots continue.

Enforcement risk during the extension period remains unclear. The bill does not grant safe harbor for entities actively implementing systems, nor does it specify FDA's inspection priorities during 2026-2027. Distributors should assume FDA will continue to enforce existing transaction documentation requirements and may increase scrutiny of system readiness.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these entities, 1,234 hold active FDA registration — a baseline compliance signal under 21 U.S.C. § 360, but not an indicator of DSCSA serialization readiness. FDA registration data does not capture warehouse management system capabilities, EPCIS integration status, or verification system deployment.

The current compliance score distribution suggests significant variation in regulatory preparedness across the industry. Of the 1,275 entities in the directory:

• 28 entities (2.2%) score in the "Excellent" range (85-100 points)
• 281 entities (22.0%) score "Good" (70-84 points)
• 919 entities (72.1%) score "Fair" (40-69 points)
• 38 entities (3.0%) score "Poor" (20-39 points)
• 9 entities (0.7%) score "Minimal" (0-19 points)

The average compliance score of 51/100 places the median entity in the "Fair" category. This score reflects publicly verifiable data points — state licensure, NABP accreditation status, FDA registration, and enforcement history — not serialization system readiness, which is not publicly reportable. However, entities scoring below 40 points often lack complete state licensure or have enforcement actions on record, suggesting they face compounding compliance challenges beyond DSCSA serialization.

Only 63 entities in the directory hold NABP accreditation (formerly VAWD), which requires adherence to NABP Model Rules for the Licensure of Wholesale Distributors. NABP accreditation does not directly assess DSCSA serialization capabilities, but accredited entities typically maintain more comprehensive quality management systems, which correlates with faster technology adoption rates.

73 entities in the directory have FDA recalls on record, indicating prior supply chain issues. These entities face heightened scrutiny during DSCSA enforcement and may be prioritized for FDA inspection during the 2026-2027 extension period.

Practical Guidance for Compliance Officers

If you are qualifying or monitoring wholesale drug distributors as trading partners, consider the following steps in response to the H.R. 1233 delay:

• Re-assess vendor qualification timelines: Distributors that were flagged as non-compliant in Q3-Q4 2025 may now remain viable trading partners through 2027. Update internal risk assessments to reflect the extended timeline, but do not remove serialization readiness as a qualification criterion — voluntary adoption may still occur.

• Verify baseline compliance posture: Use the ColdChainCheck directory to confirm that prospective trading partners hold current FDA registration and active state licenses in relevant jurisdictions. A distributor lacking baseline compliance signals is unlikely to meet serialization requirements even with the delay.

• Request serialization implementation plans: The delay does not eliminate the requirement — it postpones enforcement. During vendor qualification calls, request written timelines for EPCIS deployment, verification system testing, and master data governance. Entities without documented plans are higher-risk trading partners.

• Monitor enforcement actions during the extension: ColdChainCheck tracks FDA warning letters and recalls by entity. Distributors that receive enforcement actions during 2026-2027 may face accelerated compliance expectations or be excluded from the extended timeline if FDA determines their non-compliance is willful.

ColdChainCheck will continue to track publicly available DSCSA compliance signals as they become reportable. For ongoing regulatory developments, see the Compliance Guides section.

Disclaimer: This article is informational only and does not constitute legal or regulatory advice. Entities subject to DSCSA requirements should consult qualified legal counsel and verify all compliance obligations with the FDA and relevant state boards of pharmacy.